Affimed (NASDAQ:AFMD) Given Consensus Recommendation of “Moderate Buy” by Analysts

Affimed (NASDAQ:AFMD) has earned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $16.00.

A number of brokerages have issued reports on AFMD. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Affimed in a research note on Friday, November 15th. Stifel Nicolaus dropped their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a report on Friday, November 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a report on Tuesday.

Affimed Stock Down 2.9 %

Shares of Affimed stock opened at $2.64 on Friday. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a 12-month low of $2.64 and a 12-month high of $8.95. The firm’s 50-day moving average price is $3.43 and its two-hundred day moving average price is $4.47.

Affimed (NASDAQ:AFMD) last announced its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $1.67 million. Affimed had a negative return on equity of 193.84% and a negative net margin of 7,836.26%. As a group, sell-side analysts predict that Affimed will post -3.91 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AFMD. Jane Street Group LLC bought a new position in Affimed in the 3rd quarter valued at approximately $44,000. Choreo LLC bought a new position in Affimed in the 2nd quarter valued at approximately $54,000. FMR LLC raised its holdings in Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares during the last quarter. Intellectus Partners LLC raised its holdings in Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 10,250 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 15,108 shares during the last quarter. Institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.